Upstream Bio, Inc. (UPB)

Upstream Bio, Inc.'s stock has increased significantly, including a 154.27% rise and a 60% rally since early September 2025, following positive Phase 2 data for verekitug in CRSwNP. Upcoming events include Phase 2 data release for severe asthma in Q1 2026 and an ongoing Phase 2 study for COPD. The company was included in the NASDAQ Biotechnology Index in December 2025. Analyst ratings are generally positive, with a consensus of "Moderate Buy" and an average 1-year price objective of $45.25.

Upstream Bio, Inc. does not currently experience commercial demand seasonality for its products or services, as verekitug is still in clinical development. Meaningful revenue from verekitug is not anticipated before 2029 or 2030.

Upstream Bio, Inc. is a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders. Their main product candidate, verekitug, is a monoclonal antibody targeting Thymic Stromal Lymphopoietin (TSLP) and is in Phase 2 clinical development for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and in Phase 1 clinical trial for chronic obstructive pulmonary disease (COPD).

Upstream Bio, Inc. is headquartered in Waltham, Massachusetts, United States. While primarily based in the U.S., the company is open to international partnerships in over 45 countries, especially in regions with high respiratory disease prevalence. They have also received revenue from a Japanese pharmaceutical company, Maruho.

Upstream Bio's brand reputation has been positively influenced by strong clinical trial results and favorable analyst coverage. Verekitug's "best-in-class" Phase 2 data for CRSwNP has contributed to a positive perception. Analysts have initiated coverage with positive ratings, citing the outlook for verekitug in asthma. The company's inclusion in the NASDAQ Biotechnology Index has enhanced its visibility.

Upstream Bio, Inc. has significant institutional ownership, with 204 institutional owners holding 46,339,921 shares. Major institutional owners include Fmr Llc, Orbimed Advisors Llc, Decheng Capital LLC, BlackRock, Inc., Enavate Sciences GP, LLC, Vanguard Group Inc, Bain Capital Life Sciences Investors, LLC, TCG Crossover Management, LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, and Altshuler Shaham Ltd. Key individual and insider owners include Erez Chimovits, Upstream Llc Ai (controlled by Len Blavatnik), and Advisors Llc Orbimed. Institutional investors hold approximately 65.82% to 84.04% of the company's stock, while insiders hold around 8.43% to 29.04%.